Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
20 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Blood · 2021
AbstractMeasurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus. All recommendations are graded by levels of evidence and agreement. Major changes include technical specifications for next-generation sequencing-based MRD testing and integrative assessments of MRD irrespective of technology. Other topics include use of MRD as a prognostic and surrogate end point for drug testing; selection of the technique, material, and appropriate time points for MRD assessment; and clinical implications of MRD assessment. In addition to technical recommendations for flow- and molecular-MRD analysis, we provide MRD thresholds and define MRD response, and detail how MRD results should be reported and combined if several techniques are used. MRD assessment in AML is complex and clinically relevant, and standardized approaches to application, interpretation, technical conduct, and reporting are of critical importance.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 1993
Abstract An anabolic effect on bone of intermittent parathyroid hormone (PTH) treatment has been found in patients with osteoporosis and also in experimental animals. Controversies exist, however, about whether the positive effect on the trabecular bone balance occurs at the expense of the cortical bone. We examined the biomechanical quality of cortical bone after intermittent treatment with different doses of PTH and, furthermore, compared the effects of PTH-(1–34) and PTH-(1–84). Groups of rats were treated with biosynthetic human PTH-(1–34) or PTH-(1–84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days. No changes in the body weights and no changes in the lengths of the femora were observed after the PTH treatments. The bio-mechanical properties were analyzed by means of a materials-testing machine. A dose-related increase in the bending strength and stiffness of the femora was found, and this increase in mechanical strength corresponds with a 9–12% increase in the cross-sectional area of the femoral diaphyses. The deflection capability and energy absorption were not influenced by any of the PTH treatments. No differences were found between the effects of PTH-(1–34) or PTH-(1–84) on the biomechanical properties of the femora. Consequently, intermittent treatment with biosynthetic PTH-(1–34) or PTH-(1–84) increased the formation of cortical bone, and the biomechanical competence of the femora was found to be preserved.
HemaSphere · 2022
Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts from the MRD Working Party of the European LeukemiaNet evaluated which aspects are crucial for accurate MFC-MRD measurement. Here, we report on the agreement, obtained via a combination of a cross-sectional questionnaire, live discussions, and a Delphi poll. The recommendations consist of several key issues from bone marrow sampling to final laboratory reporting to ensure quality and reproducibility of results. Furthermore, the experiences were tested by comparing two 8-color MRD panels in multiple laboratories. The results presented here underscore the feasibility and the utility of a harmonized theoretical and practical MFC-MRD assessment and are a next step toward further harmonization.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Bone & joint open · 2023 · Journal Article
Jørgensen PB, Jakobsen SS, Vainorius D, Homilius M, et al.
HemaSphere · 2022 · Journal Article
Tettero JM, Freeman S, Buecklein V, Venditti A, et al.
BMJ case reports · 2021 · Case Reports
Jørgensen AR, Jørgensen PH, Jul Kiil B, Stilling M
Acta orthopaedica Belgica · 2018 · Journal Article
Kristensen MS, Jørgensen PB, Bogh SB, Kierkegaard S, et al.
European heart journal. Acute cardiovascular care · 2017 · Clinical Trial, Phase I
Nochioka K, Biering-Sørensen T, Hansen KW, Sørensen R, et al.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2014 · Consensus Statement
Restrepo C, Schmitt S, Backstein D, Alexander BT, et al.
Ugeskrift for laeger · 2010 · English Abstract
Jørgensen PH, Fuursted K, Holmstrup P, Husted H, et al.
Ugeskrift for laeger · 2007 · English Abstract
Jørgensen PS, Konradsen LA, Mati WB, Tørholm C
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 1993 · Journal Article
Ejersted C, Andreassen TT, Oxlund H, Jørgensen PH, et al.
Acta oncologica (Stockholm, Sweden) · 2023 · Randomized Controlled Trial
Jørgensen PL, Kreiberg M, Jørgensen N, Juul A, et al.
BMJ open · 2023 · Clinical Trial Protocol
Jønck S, Adamsen ML, Højgaard P, Rasmussen IE, et al.
Journal of internal medicine · 1993 · Case Reports
Jørgensen P, Hansen PR
Ugeskrift for laeger · 1991 · Case Reports
Jørgensen P, Hansen PR
Musculoskeletal science & practice · 2022 · Journal Article
Foldager F, Jørgensen PB, Tønning LU, Petersen ET, et al.
Acta orthopaedica · 2022 · Randomized Controlled Trial
Jørgensen PB, Tabori-Jensen S, Mechlenburg I, Homilius M, et al.
Musculoskeletal science & practice · 2022 · Journal Article
Foldager F, Jørgensen PB, Tønning LU, Petersen ET, et al.
Blood · 2021 · Journal Article
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, et al.
Blood · 2021 · Journal Article
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, et al.
Acta orthopaedica · 2019 · Journal Article
Jørgensen PB, Lamm M, Søballe K, Stilling M
Acta orthopaedica · 2022 · Randomized Controlled Trial
Jørgensen PB, Tabori-Jensen S, Mechlenburg I, Homilius M, et al.
Acta orthopaedica · 2022 · Journal Article
Breddam Mosegaard S, Jørgensen PB, Storgaard Jakobsen S, Daugaard H, et al.
Acta orthopaedica · 2020 · Journal Article
Jørgensen PB, Daugaard H, Jakobsen SS, Lamm M, et al.
Acta orthopaedica · 2019 · Journal Article
Jørgensen PB, Lamm M, Søballe K, Stilling M
Clinical rehabilitation · 2017 · Journal Article
Jørgensen PB, Bogh SB, Kierkegaard S, Sørensen H, et al.